University of Toronto, Princess Margaret Cancer Centre
Toronto, Ontario, Canada
David B. Shultz, MD.PhD: In my current position as an associate professor at the University of Toronto and a clinician at the Princess Margaret Cancer Centre, with clinician scientist salary support through the Ontario Association of Radiation Oncology, I specialize in the treatment and research of primary and metastatic central nervous system tumors. In this role, the approximate division of time between clinical and research activities is 50:50. I lead several clinical trials as principal investigator including a prospective evaluation of FLT-PET/MRI to distinguish radionecrosis from tumour progression following stereotactic radiosurgery, a longitudinal assessment of neurocognition in patients with metastatic lung cancer, and a phase II trial of neoadjuvant radiosurgery. My research goals are to increase the effectiveness and safety of brain metastasis treatments. To accomplish this, I leverage both my clinical experience treating patients at a large volume center and my extensive knowledge of basic and translational science acquired through PhD and post-doctoral studies. I currently have grants to study FLT-PET/MRI, quality of life in patients with metastatic disease, with or without brain metastases, and identification of methylated circulating tumour DNA in high grade gliomas.
